MannKind Corp (NASDAQ:MNKD)

Biotechnology word cloud

Biotech Short Interest Becomes Stock Specific

The short interest data are out for the October 15, settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
health care

Goldman Sachs Analyst Neutral Rating of MannKind Feels Like Downgrade

There had been some brief hopes that the worst was over for struggling MannKind Corp. (NASDAQ: MNKD). It turns out that not all great FDA approvals end up being great ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AIG, Align Tech, Cliffs, Cyber-Ark, MannKind, Micron and More

Stocks were lower on Monday morning after IBM issued a spoiler alert on its earnings report. Last week's bounce has shown again that investors still are willing to keep buying ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotech Becomes Company Specific

The short interest data are out for the end of September settlement date. Biotech companies are considered a riskier group of stocks with big upside and big downside. FDA rulings ...
Read Full Story »
Apple Watch intro

Apple Slips From 5 Most Shorted Nasdaq Stocks

In the wake of the successful launch of the new iPhones, short sellers got out of the way of Apple. Its short interest plunged nearly 30% between the September 15 ...
Read Full Story »
research

Short Sellers Make Moves in Key Biotech Stocks

The short interest report is out for the September 15 settlement date, and here 247 Wall St. has decided to focus on the biotech sector. Short sellers are often active ...
Read Full Story »
Biotechnology word cloud

Short Sellers Remain Vigilant Against Biotechs

The short interest report is out for the August 29 settlement date, and 24/7 Wall St. is focusing on the biotech sector. Short sellers are often active in biotech stocks, ...
Read Full Story »
biotech

Rising Short Interest in Biotech Stocks

The short interest data is out for the August 15 settlement date. Short sellers might be inclined to bet against biotech companies because of their volatile behavior on the charts, ...
Read Full Story »
Stock Split Image

What the Market is Telling MannKind (Updated)

MannKind Corp. (NASDAQ: MNKD) was supposed to be a huge winner on this week's news that Sanofi (NYSE: SNY) will become its global partner for its inhalable insulin Afrezza. There has ...
Read Full Story »
76764023

MannKind Secures Future of Afrezza in Major Sanofi Deal

MannKind Corp. (NASDAQ: MNKD) was supposed to be in the news for its earnings report. Instead, we got news of its strategy on how to get its Afrezza inhalable insulin ...
Read Full Story »
buy sell

Thirteen Analyst Stocks Under $10 With Huge Upside Potential

Stocks hit a new all-time this last week on the heels of a strong unemployment and jobs number. Now investors have to decide whether the next year or more will ...
Read Full Story »
MannKind Poll smaller

MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015

MannKind Corp. (NASDAQ: MNKD) has dipped back under $10 in the wake of the FDA finally giving approval for its Afrezza as inhalable insulin for diabetic patients. The move may ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Juniper Networks, Netflix, MannKind, Xerox and More

Stocks were firm on Tuesday morning during a shortened week that will be full of economic reports. 24/7 Wall St. reviews dozens of analyst research reports each morning of the ...
Read Full Story »
76764023

Poll: Where Does MannKind Stock Go in 2015 After Afrezza Approval?

MannKind Corp. (NASDAQ: MNKD) has seen its shares surge on news that it has finally won U.S. Food & Drug Administration backing. This FDA approval for Type 1 and 2 ...
Read Full Story »
biotech

Vindication for MannKind on FDA Approval

After markets closed last Friday, MannKind Corp. (NASDAQ: MNKD) announced that the U.S. Food and Drug Administration (FDA) had approved Afrezza, a rapid-acting, inhaled insulin powder that improves glycemic control ...
Read Full Story »